Background The effects of vitamin D on fractures, falls, and bone mineral density are uncertain, particularly for high vitamin D doses. We aimed to determine the effect of vitamin D supplementation on fractures, falls, and bone density.
Introduction
Vitamin D supplements have long been recommended for older people (>65 years) to treat or prevent osteoporosis, 1 with some early evidence suggesting benefits for musculoskeletal health, including increasing bone mineral density and preventing falls and fractures. 2 However, more recent systematic reviews have reported no effect of vitamin D supplementation on bone mineral density, 3 falls, 4-7 or fractures. [7] [8] [9] [10] Findings from our trial sequential analyses 6, 9 testing the hypothesis of a 15% relative risk reduction in falls or fractures showed that doing further trials of vitamin D, with or without calcium supplementation, which are similar to existing trials, are unlikely to alter the conclusion of these recent systematic reviews. However, correspondents questioned the use of this efficacy threshold and also suggested that inadequate vitamin D doses might explain these null results, 11,12 although some randomised controlled trials have reported increased risk of falls or fractures with high-dose intermittent vitamin D.
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Since the last major systematic reviews of vitamin D and musculoskeletal health were published in 2012-17, [3] [4] [5] [6] [7] [8] [9] [10] 45 randomised controlled trials of vitamin D monotherapy (n=20131) have reported on bone mineral density, falls, and fractures, increasing the number of trial participants with these outcomes by 40-85%. Most new trials have also used substantially higher doses of vitamin D than earlier trials. Consequently, the currently available set of randomised controlled trials has much greater power for meta-analysis and trial sequential analysis, and allows a detailed exploration of potentially important clinical factors in subgroup analyses, including comparisons of high and low doses of vitamin D. A comprehensive update of previous systematic reviews, meta-analyses, and trial sequential analyses, which includes the key clinical and major surrogate endpoints, is warranted. An advantage of assessing these outcomes concurrently is that an effect might be found for some endpoints whereas no effect is found for others, which could have clinical and biological relevance. Trial sequential analyses of vitamin D and bone mineral density have also not been reported previously.
Vitamin D supplements have often been co-administered with calcium supplements. Recent systematic reviews have suggested that the evidence for benefits of calcium supplements in preventing fractures, with or without vitamin D, is weak and inconsistent, 10, 16 with any effect on bone mineral density or fracture likely to be small and of doubtful clinical relevance. 10, 16, 17 Additionally, uncommon but important side-effects of calcium supplements [18] [19] [20] [21] have been identified, which contribute to an unfavourable risk-benefit profile. No large trials of co-administered calcium and vitamin D supplements have become available with fracture or falls as the primary endpoint since the previous systematic reviews. We did this systematic review, meta-analyses, and trial sequential analyses of randomised controlled trials in adults to study the effect of vitamin D supplements on the clinical musculoskeletal outcomes of fractures and falls, and the commonly used surrogate endpoint of bone mineral density. To align with recent findings on calcium supplements, and the recent design of vitamin D randomised controlled trials, we focused on randomised controlled trials that used vitamin D as monotherapy, and included randomised controlled trials that compared high doses of vitamin D with low doses.
Methods

Search strategy and selection criteria
In this systematic review, meta-analysis, and trial sequential analysis, we followed PRISMA guidelines for development of protocols 22 and reporting of systematic re views and meta-analyses. 23 We used our literature searches from previously published meta-analyses 3,6,8,9,16,17 as a starting point. We searched PubMed in December, 2015, for randomised controlled trials and recent systematic reviews of vitamin D in adults. We identified all studies from this search and our previous meta-analyses with fractures, falls, or bone density as an outcome. We then searched PubMed, Embase, and Cochrane Central on Sept 14, 2017, and Feb 26, 2018, using the term "vitamin D" and keywords shown in the appendix (p 1) for publications since 2015 (June 1, for PubMed and Embase; Jan 1, for Cochrane Central). We also searched two clinical trials databases (ClinicalTrials.gov and the WHO clinical trials portal) for completed and ongoing trials, using vitamin D as the search term. The full text of the search is described in the appendix (p 1).
Research in context
Evidence before this study We used findings from literature searches in previously published meta-analyses, which we updated by searching PubMed, Embase, and Cochrane Central on Sept 14, 2017, and Feb 26, 2018, using the search term "vitamin D", without any language restrictions. A full list of keywords is shown in the appendix. Evidence from older systematic reviews suggested vitamin D supplements might have benefits for musculoskeletal health, but more recent systematic reviews have reported no effect of vitamin D supplementation on fractures, falls, or bone mineral density. Some authors have suggested that inadequate vitamin D doses might explain these null results. At least 30 trials of vitamin D have been published since these systematic reviews, which nearly doubles the available trial results for vitamin D for these outcomes.
Added value of this study
Our meta-analyses and trial sequential analyses show that in a large number of clinical trials, vitamin D supplementation does not have clinically relevant effects on fractures, falls, and bone mineral density, and this conclusion is unlikely to be altered by future trials with similar designs. Effects of high doses of vitamin D were similar to effects of low doses, and none of the other potential modifiers of vitamin D effects were found to influence efficacy for any outcome.
Implications of all the available evidence
There is little justification for the use of vitamin D supplements to maintain or improve musculoskeletal health (except for the prevention or treatment of rickets and osteomalacia in high-risk groups), and clinical guidelines should reflect these conclusions.
See Online for appendix For the Cochrane handbook, see http://handbook-5-1.cochrane. org/
We included randomised controlled trials in adults (>18 years) comparing vitamin D supplements with untreated controls, placebo, or lower-dose vitamin D supple ments. Trials with multiple interventions (eg, coadmin istered calcium and vitamin D) were eligible, provided that the study groups differed only by the use of vitamin D. We included quasi-randomised and openlabel trials but excluded trials of hydroxylated vitamin D analogues. We included randomised controlled trials in cohorts with conditions likely to affect bone turnover or cohorts selected for specific diseases (eg, primary hyperparathyroidism, renal or hepatic disease), but analysed them separately in the initial analyses (termed selected population). We included randomised controlled trials with outcome data for total or hip fractures, falls, or bone mineral density measured with dual-energy x-ray absorptio metry at the lumbar spine, total hip, femoral neck, total body, or forearm. We excluded trials reporting bone mineral density using other techniques. We included cluster-randomised controlled trials. One author (MJB) screened titles and abstracts, two authors (MJB, AA) reviewed listings on trial registries, and two authors independently (MB, AG) reviewed the full text of potentially relevant studies. Studies included in previous meta-analyses but excluded from these meta-analyses are shown in the appendix (pp 2, 3).
Data analysis
Data about participant characteristics, study design, interventions, outcomes, funding sources and conflicts of interest were extracted by one author (MJB) and checked by a second author (AG). When data were presented only in figures, we used digital calipers to extract data. When data were reported for falls but not for fractures, we emailed the authors to request any data about fractures (appendix p 2). The risk of bias of eligible randomised controlled trials was independently assessed by two authors (MJB, AG) following the approach in the Cochrane Handbook for Systematic Reviews of Interventions. Discrep ancies in author assessments were resolved by discussion.
The co-primary endpoints were participants with at least one fracture, at least one hip fracture, or at least one fall. When multiple classifications of total fracture were reported, we used the largest number of participants with any fracture, non-vertebral fracture, or osteoporotic fracture. The secondary endpoints were the percentage change in bone mineral density from baseline at lumbar spine, total hip, femoral neck, total body, and forearm.
We grouped randomised controlled trials comparing vitamin D supplementation with controls, together with randomised controlled trials comparing vitamin D plus analyses. For bone mineral density, we used the same approach, but we also analysed the additional variable of study duration. We categorised randomised controlled trials of bone mineral density into three groups, by duration: 1 year (<1·5 years), 2 years (≥1·5 years and ≤2·5 years), and longer than 2·5 years.
We compared data for fractures and falls using relative risks with an intention-to-treat analysis using all available data and the number of participants randomly assigned to the treatment for each group. We compared bone mineral density data using the weighted difference in means. For all analyses, we pooled data using randomeffects models, assessed heterogeneity using the I² statistic (I² >50% was considered significant heterogeneity), and assessed systematic bias using funnel plots and Egger's test (Comprehensive Meta-Analysis, version 2). All tests were two-tailed and p values less than 0·05 were considered to be significant. We adjusted the sample size of cluster-randomised controlled trials in accordance with the Cochrane handbook. Raw bone mineral density and absolute change from baseline were converted to percentage change using the methods described in the Cochrane handbook. For studies that reported mean bone mineral density but not a measure of spread, we imputed the SD using the median sitespecific, duration-specific, and treatment-group-specific SD from other included studies, and separately analysed these studies to determine the effect of this approach.
We did a trial sequential analysis 24, 25 for each outcome (TSA Viewer, version 0.9.5.10 beta). This is a type of cumulative meta-analysis that reduces the risk of falsepositive results from repetitive statistical testing and reports the information size, an estimate of the optimum sample size for statistical inference, and estimates of treatment effects and thresholds for statistical significance and futility, taking into account multiple statistical tests. 24, 25 For fractures and falls, we initially used a 15% relative risk reduction threshold, similar to our previous publications, 6,9 and in further analyses we used progressively smaller thresholds until the optimum sample size exceeded the actual sample size. For bone mineral density, we initially used a threshold of a 3% increase, representing the approximate average bone mineral density loss of a late post-meno pausal woman over 2-4 years, and then progressively smaller thresholds. To accommodate heterogeneity between trial results, we used the larger of 15% or the calculated heterogeneity from the meta-analysis of included randomised controlled trials in the trial sequential analysis.
We did prespecified subgroup analyses to test for interactions between the effects of vitamin D supplementation on fractures, falls, and bone mineral density for the following factors, each of which is frequently invoked as a possible modifier of the effects of vitamin D: age (<65 years vs ≥65 years), BMI (<30 vs ≥30 kg/m²), baseline 
, dose of vitamin D (≤800 IU/day vs >800 IU/day, low vs high dose treat ment arms within individual studies), intermittent versus daily dosing, trials at overall low risk of bias versus trials at moderate or high risk of bias, trial duration (≤1 year vs >1 year), trial size (≤200 vs >200 participants), use of co-administered treatment versus no co-administered treatment, and location (residential care vs community dwelling). For inter mittent doses in which the daily equivalent dose is approximately 800 IU/day (eg, 300 000 IU per year), we included these trials in the 800 IU/day or less group. All such trials had an equivalent daily dose of less than 1000 IU.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility to submit for publication.
Results
We identified 81 eligible randomised controlled trials of vitamin D supplements (n=53 537 participants)
13-15, that reported fractures (n=42), falls (n=37), or bone mineral density (n=41) as an outcome (figure 1). The study design and selected baseline characteristics of the included trials are shown in the appendix (pp 4-9) and summarised in 30 Komulainen et al (1998) 31 Pfeifer et al (2000) 34 Meyer et al (2002) 36 Trivedi et al (2003) 40 Avenell et al (2004) 41 Harwood et al (2004) 43 Flicker et al (2005) 45 Grant et al (2005) 46 Law et al (2006) 49 Burleigh et al (2007) 52 Lyons et al (2007) 53 Smith et al (2007) 54 Prince et al (2008) 56 Janssen et al (2010) 61 Sanders et al (2010) 12 Glendenning et al (2012) 68 MacDonald et al (2013) 73 Hansen et al (2015) 85 Uusi-Rasi et al (2015) 88 Hin et al (2017) 96 Khaw et al (2017) 97 Larsen et al (2018) 98 Smith et al (2017) 104 Total Heterogeneity: I 2 =13%, p=0·28
High vs low dose Bischoff-Ferrari et al (2010) 14 Grimnes et al (2012) 69 Mak et al (2016) 91 Ginde et al (2017) 95 Total Heterogeneity: I 2 =0%, p=0·66
Selected population
Witham et al (2010) 62 Mitri et al (2011) 63 Punthakee et al (2012) 75 Witham et al (2013) 77 Breslavsky et al (2014) 78 Massart et al (2014) 79 Baron et al (2015) 83 Schwetz et al (2017) L ip s e t a l ( 1 9 9 6 ) 3 0 K o m u la in e n e t a l ( 1 9 9 8 ) 3 1 P f e if e r e t a l ( 2 0 0 0 ) 3 4 T r iv e d i e t a l ( 2 0 0 3 ) 4 0 A v e n e ll e t a l ( 2 0 0 4 ) 4 1 H a r w o o d e t a l ( 2 0 0 4 ) 4 3 F li c k e r e t a l ( 2 0 0 5 ) 4 5 G r a n t e t a l ( 2 0 0 5 ) 4 6 B u r le ig h e t a l ( 2 0 0 7 ) 5 2 S m it h e t a l ( 2 0 0 7 ) 5 4 P r in c e e t a l ( 2 0 0 8 ) 5 6 B is c h o ff -F e r r a r i e t a l ( 2 0 1 0 ) 1 4 Ja n s s e n e t a l ( 2 0 1 0 ) 6 1 S a n d e r s e t a l ( 2 0 1 0 ) 1 3 W it h a m e t a l ( 2 0 1 0 ) 6 2 G le n d e n n in g e t a l ( 2 0 1 2 ) 6 8 G r im n e s e t a l ( 2 0 1 2 ) 6 9 M a c D o n a ld e t a l ( 2 0 1 3 ) 7 3 P u n t h a k e e t a l ( 2 0 1 2 ) 7 5 W it h a m e t a l ( 2 0 1 3 ) 7 7 M a s s a r t e t a l ( 2 0 1 4 ) 7 9 B a r o n e t a l ( 2 0 1 5 ) 8 3 H a n s e n e t a l ( 2 0 1 5 ) 8 5 U u s i-R a s e t a l ( 2 0 1 5 ) 8 8 M a k e t a l ( 2 0 1 6 ) 9 1 G in d e e t a l ( 2 0 1 7 ) 9 5 K h a w e t a l ( 2 0 1 7 ) 9 7 L a r s e n e t a l ( 2 0 1 7 ) 9 8 S c h w e t z e t a l ( 2 0 1 7 ) 1 0 3 S m it h e t a l ( 2 0 assessment of risk of bias and conflicts of interest and funding source are shown in the appendix (pp 10-14). Ten (24%) of 42 trials were considered to be at low risk of bias for fractures, 19 (51%) of 37 were at low risk of bias for falls, and 29 (71%) of 41 were at low risk of bias for bone mineral density. The outcome data for each study for each endpoint are shown in the appendix (pp 15
between trials in selected and unselected populations. Therefore, we pooled all the trials, and found no effect of vitamin D supplementation on total fracture (36 trials, n=44 790; relative risk [RR] 1·00, 95% CI 0·93-1·07), hip fracture (20 trials, n=36 655; 1·11, 0·97-1·26), or falls (37 trials, n=34 144; 0·97, 0·93-1·02). Using Egger's regression model and visual inspection of funnel plots, data appeared skewed toward a reduction in events with vitamin D sup plementation for all primary outcomes, largely because of an excess of studies of small-to-medium size with positive effects on the outcomes (data not shown).
In trial sequential analyses of total fracture and falls, the effect estimate lay within the futility boundary for relative risks of 15%, 10%, 7·5%, and 5% (total fracture only) providing reliable evidence that vitamin D supplementation does not reduce fractures and falls by these amounts (figures 2, 3; table 2). For hip fracture, at a 15% RR, the effect estimate lay between the futility boundary and the inferior boundary, meaning there is reliable evidence that vitamin D supplementation does not reduce hip fractures by this amount, but uncertainty remains as to whether it might increase hip fractures (table 2; appendix p 20). Figure 4 and the appendix (pp [21] [22] [23] [24] [25] [26] [27] show the results of the meta-analysis for bone mineral density. First, we compared the results of trials with missing measures of spread and imputed SDs to the other trials, by duration, design, and population. Generally, there was little difference between results, and therefore we included the trials with imputed SDs in subsequent analyses 34 Bischoff et al (2003) 37 Latham et al (2003) 39 Trivedi et al (2003) 40 Dhesi et al (2004) 42 Harwood et al (2004) 43 Flicker et al (2005) 45 Bunout et al (2006) 48 Law et al (2006) 49 Broe et al (2007) 51 Burleigh et al (2007) 52 Smith et al (2007) 54 Prince et al (2008) 56 Sanders et al (2010) 13 Glendenning et al (2012) 68 MacDonald et al (2013) 73, 74 Rizzoli et al (2014) 81 Cangussu et al (2015) 84 Hansen et al (2015) 85 Houston et al (2015) 86 Uusi-Rasi et al (2015) 88 Aloia et al (2017) 93 Hin et al (2017) 96 Khaw et al (2017) 97 Levis et al (2017) 99 Smith et al (2017) 104 Total Heterogeneity: I 2 =38%, p=0·03
High vs low dose Bischoff-Ferrari et al (2010) 14 Bischoff-Ferrari et al (2016) 15 Mak et al (2016) 91 Ginde et al (2017) 95 Total Heterogeneity: I 2 =78%, p<0·01
Witham et al (2010) 62 Witham et al (2013) 77 Massart et al (2014) 79 Jin et al (2016) 90 Schwetz All studies (n=37) Heterogeneity: I 2 =41%, p<0·01
Vitamin D (n/N) Control (n/N) Weight (%) Relative risk of falls (95% CI) A G r a a f m a n s e t a l ( 1 9 9 6 ) 2 9 P f e if e r e t a l ( 2 0 0 0 ) 3 4 B is c h o ff e t a l ( 2 0 0 3 ) 3 7 T r iv e d i e t a l ( 2 0 0 3 ) 4 0 D h e s i e t a l ( 2 0 0 4 ) 4 2 H a r w o o d e t a l ( 2 0 0 4 ) 4 3 F li c k e r e t a l ( 2 0 0 5 ) 4 5 G r a n t e t a l ( 2 0 0 5 ) 4 6 L a w e t a l ( 2 0 0 6 ) 4 9 B u r le ig h e t a l ( 2 0 0 7 ) 5 2 S m it h e t a l ( 2 0 0 7 ) 5 4 P r in c e e t a l ( 2 0 0 8 ) 5 6 B is c h o ff -F e r r a r i e t a l ( 2 0 1 0 ) 1 4 S a n d e r s e t a l ( 2 0 1 0 ) 1 3 W it h a m e t a l ( 2 0 1 0 ) 6 2 M a c D o n a ld e t a l ( 2 0 1 3 ) 7 3 ,7 4
W it h a m e t a l ( 2 0 1 3 ) 7 7 M a s s a r t e t a l ( 2 0 1 4 ) 7 9 R iz z o li e t a l ( 2 0 1 4 ) 8 1 C a n g u s s u e t a l ( 2 0 1 5 ) 8 4 H o u s t o n e t a l ( 2 0 1 5 ) 8 6 U u s i-R a s e t a l ( 2 0 1 5 ) 8 8
B is c h o ff -F e r r a r i e t a l ( 2 0 1 6 ) 1 5 Ji n e t a l ( 2 0 1 6 ) 9 0 M a k e t a l ( 2 0 1 6 ) 9 1 A lo ia e t a l ( 2 0 1 7 ) 9 3 H in e t a l ( 2 0 1 7 ) 9 6 K h a w e t a l ( 2 0 1 7 ) 9 7 L e v is e t a l ( 2 0 1 7 ) 9 9 S c h w e t z e t a l ( 2 0 1 7 ) 1 0 3 L a t h a m e t a l ( 2 0 0 3 ) 3 9 B u n o u t e t a l ( 2 0 0 6 ) 4 8 B r o e e t a l ( 2 0 0 7 ) 5 1 G le n d e n n in g e t a l ( 2 0 1 2 ) 6 8 H a n s e n e t a l ( 2 0 1 5 ) 8 (appendix p 21). Next, we compared the results of trials by duration, study design, and population type. For all combinations of these factors, there was little difference in results between the subgroups, and therefore we pooled the trials with differing study designs (vitamin D vs controls, high-dose vs low-dose vitamin D) and those in selected and unselected populations (appendix pp [21] [22] [23] . Because there were only small differences by trial duration, we also pooled all the trials using only the final timepoint data for each trial. Figure 4 and the appendix (pp [24] [25] [26] [27] show the between-group differences in bone mineral density by site and trial duration, and the pooled analyses using the final timepoint. Betweengroup differences in bone mineral density did not consistently increase with increasing trial duration at any site, and in the pooled analyses using the final timepoint the between-group differences were 0·25% (95% CI 0·00 to 0·49) for lumbar spine, 0·34% (0·13 to 0·55) for total hip, 1·12% (0·58-1·65) for femoral neck, -0·16% (-0·46 to 0·13) for forearm, and 0·13% for total body (-0·16 to 0·42). Notably, at the femoral neck, one study 106 reported a between-group difference of 10·6% (95% CI 9·0-12·3) after 1 year, which was a clear outlier and had a disproportionate effect on the pooled result. We excluded this trial 106 from subsequent analyses, and after its exclusion, the between-group difference at the femoral neck was 0·76% (95% CI 0·42-1·09; appendix p 25). Using Egger's regression model and visual inspection of funnel plots, data appeared skewed toward increased bone mineral density with vitamin D supplementation for all sites except the forearm, again largely due to many small studies with positive effects on bone mineral density (data not shown). We did all subsequent trial sequential analyses and subgroup analyses using only the final timepoint data for each trial.
In trial sequential analysis of bone mineral density, the effect estimates for total hip, forearm, and total body lay within the futility boundary for a between-group difference of 0·5% (or more), and at the lumbar spine and femoral neck the effect estimate lay within the futility boundary for a difference of 1·0% but above the superior boundary for a difference of 0·5% (table 2; figure 4; appendix pp [24] [25] [26] [27] .
18 randomised controlled trials reported the results of a subgroup analysis using various thresholds for baseline 25OHD (appendix p 28). Three trials reported no effects of vitamin D on fracture in subgroups, and five reported no effects in subgroups or no interactions with baseline 25OHD, and one reported mixed effects of vitamin D on falls in subgroups (appendix p 28). The subgroup results in all randomised controlled trials were similar to the primary analyses in each study. For bone mineral density, one trial reported positive effects in subgroups, five trials reported mixed effects, and eight trials reported no effects in subgroups, no difference, or no interactions with baseline 25OHD (appendix p 28). In three of 14 trials reporting subgroup analyses results for bone density, some subgroup results were different to the primary analysis, and in the remaining 11 trials, the subgroup results were similar to the primary analysis.
In the 12 prespecified subgroup analyses for the pri mary outcome of fractures and falls, there was only one significant interaction between vitamin D supple mentation and The RR and % difference are thresholds that indicate the relative risk reduction in falls or fractures, or the between-groups difference in bone mineral density assessed in the trial sequential analyses. RR=relative risk. BMD=bone mineral density. *Effect size was between the futility and inferior boundaries. †Effect size was between the futility and superior boundaries. ‡Only heterogeneity results shown. §Analyses were not possible because the optimum sample size was smaller than the sample size for the first trial. a factor (total fracture; effect greater in studies ≤200 participants; 36 total analyses; appendix pp 29, 30). For bone mineral density, of the 64 subgroup analyses done, there were eight significant interactions, although in four interactions there was only one trial in one of the subgroups (appendix pp 31, 32). The other four significant interactions were for total hip (effect greater without coadministered calcium), femoral neck (effect greater in smaller studies or without co-administered treatments), and total body (effect greater with higher doses). Overall, there were 100 subgroup analyses. If all the results were independent, about five statistically significant interactions would be expected by chance. In post-hoc analyses, we compared high daily dose with low daily dose randomised controlled trials, and intermittent highdose with intermittent low-dose randomised controlled trials, and there were no significant inter actions between subgroups for any outcome (data not shown).
Discussion
In meta-analyses of 81 randomised controlled trials, vitamin D supplementation did not affect incident fractures or falls, and did not have consistent clinically relevant effects on bone mineral density. There were no significant differences in results of trials comparing vitamin D with controls and trials comparing high doses with low doses of vitamin D, although there are fewer trials with the latter study design. Likewise, there was no consistent evidence of different effects in subgroup analyses based upon potentially influential baseline variables including baseline 25OHD or study design characteristics, nor of different effects in trials of high-dose vitamin D or trials with higher achieved 25OHD concentrations. Trial sequential analyses showed that there is reliable evidence that vitamin D supplementation does not have meaningful clinical benefits: it does not reduce the relative risk of total fracture by 5% or falls by 7·5%, it does not increase bone mineral density by 0·5-1%, and uncertainty remains as to whether it might increase the risk of hip fracture. Further similar trials are unlikely to alter the conclusions of these trial sequential analyses. If a large future trial has markedly different results to the current trials, adding its results will sub stantially increase the heterogeneity of the trial results, which in turn will reduce the weighting the new large trial receives in the pooled analyses. Thus, adding a positive result from a large randomised controlled trial will have only a small 26 Dawson-Hughes et al (1995) 27 Hunter et al (2000) 33 Patel et al (2001) 35 Cooper et al (2003) 38 Harwood et al (2004) 43 Aloia et al (2005) 44 Wissing et al (2005) 47 Bunout et al (2006) 48 Mikati et al (2006) 50 Andersen et al (2008) 55 Islam et al (2010) 59 Jorde et al (2010) 60 Rastelli et al (2011) 65 Grimnes et al (2012) 69 Iuliano-Burns et al (2012) 71 Bolland et al (2013) 72 MacDonald et al (2013) 73 Wamberg et al (2013) 76 Norenstedt et al (2014) 80 Rolighed et al (2014) 82 Hansen et al (2015) 85 Liyanage et al (2015) 87 Uusi-Rasi et al (2015) 88 Mason et al (2016) 92 Eckard et al (2017) 94 Pop et al (2017) 100 Rahme et al (2017) 101 Havens et al (2018) 105 Zheng et al (2018) 27 Hunter et al (2000) 33 Cooper et al (2003) 38 Aloia et al (2005) 44 Steffensen et al (2011) 66 Nieves et al (2012) 70 Uusi-Rasi et al (2015) 88 Reid et al (2017) 102 Total Heterogeneity: I 2 =0%, p=0·89 Komulainen et al (1999) 32 Aloia et al (2005) Jo r d e e t a l ( 2 0 1 0 ) 6 0 R a s t e ll i e t a l ( 2 0 1 1 ) 6 5 S t e ff e n s e n e t a l ( 2 0 1 1 ) 6 6 G r im n e e t a l ( 2 0 1 2 ) 6 9
≥3 years
Iu li ia n o -B u r n s e t a l ( 2 0 1 2 ) 7 1 N ie v e s e t a l ( 2 0 1 2 ) 7 0 M a c D o n a ld e t a l ( 2 0 1 3 ) 7 3 W a m b e r g e t a l ( 2 0 1 3 ) 7 6
N o r e n s t a d t e t a l ( 2 0 1 4 ) 8 0 R o li g h e d e t a l ( 2 0 1 4 ) 8 2 H a n s e n e t a l ( 2 0 1 5 ) 8 5 U u s i-R a s e t a l ( 2 0 1 5 ) 8 8 M a s o n e t a l ( 2 0 1 6 ) 9 2 E c k a r d e t a l ( 2 0 1 7 ) 9 4 P o p e t a l ( 2 0 1 7 ) 1 0 0 R a h m e e t a l ( 2 0 1 7 ) 1 0 1 R e id e t a l ( 2 0 1 7 ) 1 0 2 Z h e n g e t a l ( 2 0 1 8 ) 1 0 6 H u n t e r e t a l ( 2 0 0 0 ) 3 3 M ik a t i e t a l ( 2 0 0 6 ) 5 0 Is la m e t a l ( 2 0 1 0 ) 5 9 B o ll a n d e t a l ( 2 0 1 3 ) 7 2 L iy a n a g e e t a l ( 2 0 1 5 ) 8 7 H a v e n s e t a l ( 2 0 1 8 ) 1 0 5 effect on the pooled result, and is unlikely to alter the conclusions of these meta-analyses.
The strengths of the current analyses are that they are comprehensive, include all available data from a large number of new trials, and concomitantly assess the major clinical and surrogate endpoints for musculoskeletal health. The analyses are based on substantially more trials, more participants, and more events than previous analyses, which means they have greater power, the effect estimates have greater precision, the trial sequential analyses are able to examine efficacy at lower RR thresh olds, and the subgroup analyses are more comprehensive. The trial sequential analyses are important because they provide estimates about the reliability of current evidence and the likelihood of future trials to change current conclusions. The number of studies included permitted a large number of subgroup analyses exploring the effects of potentially relevant trial and participant characteristics, some of which have been invoked as explanations for the null findings of individual trials of vitamin D. The greater number of trials with bone mineral density as an outcome allowed us to examine the effects of vitamin D supplementation in trials of differing durations, which showed no evidence that between-group differences in bone mineral density increased as trial duration increased.
These analyses also have limitations. We included studies with methodological limitations, although there was no evidence that randomised controlled trials at low risk of bias reported substantially different effects. Several meta-analyses had moderate heterogeneity in trial results, generally because a few studies of small-to-moderate size reported positive results that were not observed in larger trials. The subgroup analyses show that, for all outcomes, smaller studies of shorter duration tended to have inflated effect sizes compared with larger and longer studies, such that the results of small, short-duration studies should be interpreted very cautiously, since they might not be replicated in larger, longer studies. Heterogeneity of popu lations, study designs, and results is also an issue for trial sequential analyses. Although the heterogeneity in the existing results is incorporated into the trial sequential analysis calcu lations, assumptions about the results of future large trials are based on the expectation that they will be similar to the existing trials. For vitamin D, this seems a reasonable assumption given the consistency among existing trial results, particularly among large random ised controlled trials. Data were collected differently for falls in different trials, which might affect the study findings, although these results were independent of our assessment of the risk of bias.
The results from these meta-analyses are consistent with most of the recent systematic reviews of vitamin D supplementation on musculoskeletal outcomes, 3, 6, 7, 9, 10 including those from the Cochrane groups, 4, 5, 8 and align with the recent statements from the US Preventative Services Taskforce, which recommends against vitamin D supplementation to prevent falls 107 or fractures 108 in community-dwelling adults. Some previous meta-analyses reached more optimistic conclusions as a result of differences in trial selection and outcome definition, and use of per-protocol rather than intention-to-treat analysis. 109, 110 The differences in meta-analyses results might explain why some clinical guidelines continue to recommend vitamin D supplementation for musculo skeletal indications, 111, 112 which seems incon sistent with the available evidence.
There have been several explanations for the absence of meaningful effects of vitamin D on musculoskeletal outcomes. These have included that the baseline 25OHD concentrations of trial participants have been too high, the doses of vitamin D supplements too low, or that trials have been inadequately designed, underpowered, or done in the wrong populations. None of those explanations seems likely to account for our findings. The trials we included have a broad range of study designs and populations, but there are consistently neutral results for all endpoints, including the surrogate endpoint of bone mineral density. In summary, vitamin D supplementation did not have meaningful effects on fracture, falls, or bone mineral density, and future trials are unlikely to alter these conclusions. Therefore, there is little justification for the use of vitamin D supplements to maintain or improve musculoskeletal health, and clinical guidelines should reflect these findings. The clear exception to this is for the prevention or treatment of the rare conditions of rickets and osteomalacia, which can occur after a prolonged lack of exposure to sunshine that leads to 25OHD concentrations lower than 25 nmol/L. We believe there is no justification for more trials of vitamin D supplements with musculoskeletal outcomes because there is no longer equipoise about the effects of vitamin D on these outcomes. Trials of vitamin D supplementation in individuals with marked vitamin D deficiency, who are not at risk of osteomalacia, might produce different results, but require a strong scientific rationale before being undertaken, given the absence of effects of vitamin D seen in existing trials.
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